Exelixis' cabozantinib meets in Phase II for first-line thyroid cancer
Exelixis Inc. (NASDAQ:EXEL) said once-daily 60 mg oral cabozantinib as first-line treatment met the primary endpoint of objective response rate (ORR) in a Phase II trial to treat metastatic radioiodine-refractory differentiated thyroid cancer. The pre-specified ORR threshold to meet the endpoint was about 15% or at least 5 responses out of 35 patients. Specifically, cabozantinib led to an ORR of 54% -- all partial responses -- in 35 evaluable patients.
Secondary endpoints in the open-label, U.S. trial include progression-free survival (PFS), time to progression, duration of response and clinical benefit rate (CBR). Median PFS has not been reached at a median follow-up of 35 weeks...